Показано 0 из 0
Дата |
---|
03.05.2024 |
02.05.2024 |
01.05.2024 |
30.04.2024 |
29.04.2024 |
26.04.2024 |
25.04.2024 |
24.04.2024 |
23.04.2024 |
22.04.2024 |
Bid | Ask |
Open |
Min | Max |
Last |
Legal close |
Avg |
Оборот |
Кол-во сделок |
---|---|---|---|---|---|---|---|
9.27
|
10.03
|
8.465
|
8.465
|
10.25
|
9.575
|
|
|
352 029.94
|
622.00
|
7.99
|
8.39
|
8.42
|
8.18
|
8.78
|
8.46
|
|
|
336 619.68
|
637.00
|
8.16
|
9.07
|
9.04
|
8.20
|
9.15
|
8.22
|
|
|
300 730.86
|
535.00
|
8.62
|
9.06
|
9.97
|
9.04
|
9.97
|
9.08
|
|
|
168 072.59
|
423.00
|
9.83
|
10.14
|
8.24
|
8.24
|
10.14
|
9.97
|
|
|
384 256.54
|
486.00
|
8.20
|
8.60
|
8.57
|
8.20
|
8.69
|
8.49
|
|
|
180 398.79
|
399.00
|
8.40
|
8.83
|
9.50
|
7.88
|
9.88
|
8.43
|
|
|
1 373 143.12
|
1 977.00
|
10.79
|
10.89
|
9.87
|
9.05
|
9.87
|
9.48
|
|
|
903 745.39
|
1 106.00
|
9.50
|
11.73
|
9.56
|
9.335
|
10.11
|
9.81
|
|
|
526 908.43
|
869.00
|
9.30
|
11.66
|
9.58
|
9.06
|
9.92
|
9.51
|
|
|
641 006.31
|
642.00
|
Acrivon is a clinical stage biopharmaceutical company developing precision oncology medicines that it matches to patients whose tumors are predicted to be sensitive to each specific medicine by utilizing Acrivon’s proprietary proteomics-based patient responder identification platform, Acrivon Predictive Precision Proteomics, or AP3.